- Home
- LYRA vs STAI Comparison
LYRA vs STAI Comparison
Compare LYRA & STAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- STAI
- Stock Information
- Founded
- LYRA 2005
- STAI 2011
- Country
- LYRA United States
- STAI United States
- Employees
- LYRA N/A
- STAI N/A
- Industry
- LYRA Medical/Dental Instruments
- STAI
- Sector
- LYRA Health Care
- STAI
- Exchange
- LYRA Nasdaq
- STAI Nasdaq
- Market Cap
- LYRA 15.0M
- STAI 16.6M
- IPO Year
- LYRA 2020
- STAI N/A
- Fundamental
- Price
- LYRA $7.95
- STAI $0.64
- Analyst Decision
- LYRA Buy
- STAI
- Analyst Count
- LYRA 2
- STAI 0
- Target Price
- LYRA $16.00
- STAI N/A
- AVG Volume (30 Days)
- LYRA 91.5K
- STAI 477.4K
- Earning Date
- LYRA 08-13-2025
- STAI 01-01-0001
- Dividend Yield
- LYRA N/A
- STAI N/A
- EPS Growth
- LYRA N/A
- STAI N/A
- EPS
- LYRA N/A
- STAI N/A
- Revenue
- LYRA $1,185,000.00
- STAI $542,166.00
- Revenue This Year
- LYRA N/A
- STAI N/A
- Revenue Next Year
- LYRA $139.18
- STAI N/A
- P/E Ratio
- LYRA N/A
- STAI N/A
- Revenue Growth
- LYRA N/A
- STAI N/A
- 52 Week Low
- LYRA $3.81
- STAI $0.62
- 52 Week High
- LYRA $37.50
- STAI $9.07
- Technical
- Relative Strength Index (RSI)
- LYRA 41.08
- STAI N/A
- Support Level
- LYRA $7.77
- STAI N/A
- Resistance Level
- LYRA $8.67
- STAI N/A
- Average True Range (ATR)
- LYRA 0.45
- STAI 0.00
- MACD
- LYRA -0.03
- STAI 0.00
- Stochastic Oscillator
- LYRA 11.32
- STAI 0.00
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.